Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium
Journal of Antimicrobial Chemotherapy · 02.08.2023 · 78 (8) · 2061-2065
DOI: 10.1093/jac/dkad204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 26.06.2023. Verfasst von Ariane Deplano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, LHUB-ULB, National Reference Centre for Staphylococcus aureus and other species, Université libre de Bruxelles, route de …. Hauptthemen laut MEDLINE: Impetigo, Staphylococcal Infections, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Belgian National Institute of Health.
Abstract (Originalsprache)
Objectives
In August 2018, a public health alert was issued in Belgium regarding clusters of impetigo cases caused by the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus. As a result, the Belgian national reference centre (NRC) was commissioned to update the epidemiology of S. aureus causing community-onset skin and soft tissues infection (CO-SSTI) to assess the proportion of EEFIC among them.
Methods
For 1 year, Belgian clinical laboratories were asked to send their first three S. aureus isolated from CO-SSTI each month. Isolates were tested for antimicrobial susceptibility to oxacillin, mupirocin and fusidic acid. Resistant isolates were also spa typed and tested for the presence of the genes encoding the Panton–Valentine leucocidin, the toxic shock syndrome toxin and the exfoliatins A and B. MLST clonal complexes were deduced from the spa types.
Results
Among the 518 S. aureus strains analysed, 487 (94.0%) were susceptible to oxacillin. Of these, 79 (16.2%) were resistant to fusidic acid, of which 38 (48.1%) belonged to the EEFIC. EEFIC isolates were mostly isolated from young patients with impetigo and showed a seasonal late summer peak.
Conclusions
These results suggest the persistence of EEFIC in Belgium. Furthermore, its prevalence may lead to reconsideration of the treatment guidelines for impetigo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, LHUB-ULB, National Reference Centre for Staphylococcus aureus and other species, Université libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium.
- Centre for Environmental Health and Occupational Health, Public Health School, Université libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium.
- Scientific Directorate of Epidemiology and Public Health, Sciensano, J. Wytsmanstraat 14, 1050 Brussels, Belgium.
ORCID-Profile: Ariane Deplano, Marie Hallin, Natalia Bustos Sierra, Charlotte Michel, Delphine Martiny, Nicolas Yin
Förderung
- Belgian National Institute of Health
Zitieren
APA
Deplano, A., Hallin, M., Bustos Sierra, N., Michel, C., Prevost, B., Martiny, D., & Yin, N. (2023). Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium. Journal of Antimicrobial Chemotherapy, 78(8), 2061-2065. https://doi.org/10.1093/jac/dkad204
Vancouver
Deplano A, Hallin M, Bustos Sierra N, Michel C, Prevost B, Martiny D, et al. Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium. Journal of Antimicrobial Chemotherapy. 2023;78(8):2061-2065. doi:10.1093/jac/dkad204
BibTeX
@article{Deplano2023,
author = {Deplano, Ariane and Hallin, Marie and Bustos Sierra, Natalia and Michel, Charlotte and Prevost, Benoit and Martiny, Delphine and Yin, Nicolas},
title = {Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {8},
pages = {2061--2065},
doi = {10.1093/jac/dkad204}
}
EUVIMED